Interesting ImagesComplete Metabolic Response Assessed by FDG PET/CT to Paclitaxel-Ramucirumab in Patients With Metastatic Gastroesophageal Junction CancerAmrane, Karim MD*; Querellou, Solène MD†,‡; Schick, Ulrike MD, PhD§; Abgral, Ronan MD, PhD†,‡; Metges, Jean-Philippe MD*Author Information From the *Department of Oncology, University Hospital of Brest †EA 3878 GETBO, IFR 148, Bretagne Loire University Departments of ‡Nuclear Medicine §Radiotherapy, University Hospital of Brest, Brest, France. Received for publication May 18, 2019; revision accepted October 7, 2019. Conflicts of interest and sources of funding: none declared. Correspondence to: Karim Amrane, MD, Department of Oncology, University Hospital of Brest, 2 Avenue Foch, 29609 Brest Cedex, France. E-mail: firstname.lastname@example.org. Online date: December 24, 2019 Clinical Nuclear Medicine: February 2020 - Volume 45 - Issue 2 - p 127-128 doi: 10.1097/RLU.0000000000002882 Buy Metrics Abstract Paclitaxel-ramucirumab chemotherapy is indicated in second line of metastatic gastroesophageal junction cancer (mGEJC) after progression under platinum–5-FU chemotherapy. Nevertheless, the reported common response after treatment is only partial within series. To date, only 1 case report of negative posttreatment FDG PET/CT was published without baseline examination from RAINBOW trial. We illustrated the interest of FDG PET/CT to evaluate treatment especially paclitaxel-ramucirumab with 2 examples of complete metabolic responses in 2 patients having different HER2 biomarker profiles of mGEJC. As illustrated, FDG PET/CT emerges as a useful approach for therapeutic assessment of targeted drugs in mGEJC. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.